Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Deep Brain Stimulation | 12 | 2023 | 49 | 3.080 |
Why?
|
| Parkinson Disease | 13 | 2023 | 87 | 2.140 |
Why?
|
| Movement Disorders | 5 | 2019 | 26 | 1.980 |
Why?
|
| Subthalamic Nucleus | 6 | 2023 | 13 | 1.070 |
Why?
|
| Essential Tremor | 3 | 2023 | 12 | 1.060 |
Why?
|
| Voice Disorders | 1 | 2023 | 5 | 0.880 |
Why?
|
| Dysphonia | 2 | 2019 | 8 | 0.830 |
Why?
|
| Deglutition Disorders | 1 | 2019 | 51 | 0.640 |
Why?
|
| Weight Gain | 2 | 2015 | 117 | 0.570 |
Why?
|
| Quality of Life | 5 | 2023 | 946 | 0.570 |
Why?
|
| Levodopa | 4 | 2022 | 14 | 0.530 |
Why?
|
| Carbidopa | 3 | 2022 | 3 | 0.510 |
Why?
|
| Aged | 21 | 2023 | 10301 | 0.490 |
Why?
|
| Antiparkinson Agents | 5 | 2022 | 10 | 0.440 |
Why?
|
| Laughter | 2 | 2010 | 3 | 0.420 |
Why?
|
| Middle Aged | 21 | 2023 | 11817 | 0.380 |
Why?
|
| Pseudobulbar Palsy | 1 | 2010 | 5 | 0.360 |
Why?
|
| Mood Disorders | 1 | 2010 | 21 | 0.360 |
Why?
|
| Female | 22 | 2023 | 19959 | 0.350 |
Why?
|
| Male | 20 | 2023 | 19165 | 0.340 |
Why?
|
| Humans | 29 | 2023 | 32005 | 0.340 |
Why?
|
| Crying | 1 | 2009 | 2 | 0.330 |
Why?
|
| Affective Symptoms | 1 | 2009 | 16 | 0.330 |
Why?
|
| Treatment Outcome | 13 | 2023 | 3306 | 0.300 |
Why?
|
| Prevalence | 3 | 2019 | 981 | 0.270 |
Why?
|
| Weight Loss | 1 | 2010 | 480 | 0.270 |
Why?
|
| Globus Pallidus | 2 | 2019 | 8 | 0.250 |
Why?
|
| Droxidopa | 1 | 2014 | 1 | 0.250 |
Why?
|
| Hypotension, Orthostatic | 1 | 2014 | 13 | 0.240 |
Why?
|
| Glutamate Decarboxylase | 2 | 2017 | 17 | 0.240 |
Why?
|
| Tremor | 2 | 2023 | 11 | 0.240 |
Why?
|
| Posture | 1 | 2014 | 55 | 0.240 |
Why?
|
| Gels | 3 | 2022 | 31 | 0.220 |
Why?
|
| Alcoholism | 1 | 2023 | 101 | 0.200 |
Why?
|
| Retrospective Studies | 4 | 2019 | 3509 | 0.190 |
Why?
|
| Adult | 13 | 2023 | 9345 | 0.190 |
Why?
|
| Double-Blind Method | 6 | 2020 | 525 | 0.180 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2010 | 8 | 0.180 |
Why?
|
| Blood Pressure | 1 | 2014 | 845 | 0.180 |
Why?
|
| Aged, 80 and over | 7 | 2023 | 3990 | 0.170 |
Why?
|
| Speech Acoustics | 1 | 2019 | 4 | 0.170 |
Why?
|
| Voice Quality | 1 | 2019 | 6 | 0.170 |
Why?
|
| Dystonia | 1 | 2019 | 12 | 0.170 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 158 | 0.160 |
Why?
|
| Comorbidity | 2 | 2010 | 566 | 0.150 |
Why?
|
| Severity of Illness Index | 4 | 2020 | 881 | 0.140 |
Why?
|
| Gene Transfer Techniques | 2 | 2017 | 63 | 0.130 |
Why?
|
| Drug Combinations | 3 | 2022 | 98 | 0.120 |
Why?
|
| Intestines | 1 | 2014 | 61 | 0.120 |
Why?
|
| Brain | 2 | 2012 | 951 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2015 | 898 | 0.110 |
Why?
|
| Fibrinolytic Agents | 2 | 2002 | 70 | 0.100 |
Why?
|
| Dyskinesias | 2 | 2022 | 3 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 2265 | 0.090 |
Why?
|
| Electrodes, Implanted | 3 | 2022 | 41 | 0.090 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2010 | 6 | 0.090 |
Why?
|
| Dopamine Agonists | 1 | 2010 | 28 | 0.090 |
Why?
|
| Thiophenes | 1 | 2010 | 23 | 0.090 |
Why?
|
| Bipolar Disorder | 1 | 2010 | 16 | 0.090 |
Why?
|
| Smiling | 1 | 2010 | 1 | 0.090 |
Why?
|
| Emaciation | 1 | 2010 | 4 | 0.090 |
Why?
|
| Neurosurgical Procedures | 3 | 2010 | 99 | 0.090 |
Why?
|
| Neurology | 1 | 2010 | 45 | 0.090 |
Why?
|
| Monitoring, Intraoperative | 1 | 2010 | 42 | 0.090 |
Why?
|
| Antidepressive Agents | 1 | 2010 | 74 | 0.090 |
Why?
|
| Depressive Disorder | 1 | 2010 | 75 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2010 | 1817 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2010 | 147 | 0.090 |
Why?
|
| Health Surveys | 1 | 2010 | 196 | 0.080 |
Why?
|
| Nucleus Accumbens | 1 | 2010 | 94 | 0.080 |
Why?
|
| Florida | 1 | 2009 | 37 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2009 | 97 | 0.080 |
Why?
|
| Movement | 1 | 2009 | 51 | 0.080 |
Why?
|
| Neuropsychological Tests | 1 | 2010 | 371 | 0.080 |
Why?
|
| Motor Activity | 1 | 2010 | 325 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 633 | 0.070 |
Why?
|
| Stroke | 2 | 2003 | 585 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2022 | 2282 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2009 | 545 | 0.070 |
Why?
|
| Mental Disorders | 1 | 2008 | 121 | 0.070 |
Why?
|
| Young Adult | 2 | 2019 | 2636 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 276 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1428 | 0.060 |
Why?
|
| Educational Status | 1 | 2003 | 179 | 0.050 |
Why?
|
| Intracranial Thrombosis | 1 | 2002 | 8 | 0.050 |
Why?
|
| Neurotransmitter Agents | 1 | 2022 | 26 | 0.050 |
Why?
|
| Emotions | 1 | 2023 | 58 | 0.050 |
Why?
|
| Time Factors | 3 | 2019 | 2149 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2002 | 41 | 0.050 |
Why?
|
| Catheterization | 1 | 2002 | 58 | 0.050 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2002 | 15 | 0.050 |
Why?
|
| Hypernatremia | 1 | 2002 | 1 | 0.050 |
Why?
|
| Hyponatremia | 1 | 2002 | 3 | 0.050 |
Why?
|
| Angioplasty | 1 | 2002 | 34 | 0.050 |
Why?
|
| Vasospasm, Intracranial | 1 | 2002 | 13 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 247 | 0.050 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2002 | 26 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2002 | 68 | 0.050 |
Why?
|
| Intracranial Aneurysm | 1 | 2002 | 68 | 0.050 |
Why?
|
| Brain Ischemia | 1 | 2002 | 146 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 257 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 246 | 0.040 |
Why?
|
| Dopamine | 1 | 2023 | 232 | 0.040 |
Why?
|
| Microelectrodes | 2 | 2010 | 16 | 0.040 |
Why?
|
| Speech Intelligibility | 1 | 2019 | 5 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2003 | 475 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 767 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2019 | 199 | 0.040 |
Why?
|
| Parvovirinae | 1 | 2017 | 2 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 163 | 0.030 |
Why?
|
| Prognosis | 2 | 2010 | 1497 | 0.030 |
Why?
|
| Women's Health | 1 | 2012 | 235 | 0.020 |
Why?
|
| Hypokinesia | 1 | 2009 | 3 | 0.020 |
Why?
|
| Muscle Rigidity | 1 | 2009 | 2 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 447 | 0.020 |
Why?
|
| Cognition | 1 | 2012 | 555 | 0.020 |
Why?
|
| United States | 1 | 2017 | 3939 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 1531 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 762 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 560 | 0.020 |
Why?
|
| Social Class | 1 | 2003 | 89 | 0.010 |
Why?
|
| Risk | 1 | 2003 | 321 | 0.010 |
Why?
|
| Middle Cerebral Artery | 1 | 2002 | 13 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2002 | 100 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2002 | 83 | 0.010 |
Why?
|
| Equipment Design | 1 | 2002 | 171 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2002 | 105 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2002 | 83 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2003 | 753 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 288 | 0.010 |
Why?
|
| Carotid Artery Diseases | 1 | 2002 | 114 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2002 | 122 | 0.010 |
Why?
|
| Stents | 1 | 2002 | 177 | 0.010 |
Why?
|
| Incidence | 1 | 2003 | 1199 | 0.010 |
Why?
|
| Age Factors | 1 | 2003 | 1188 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 510 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 918 | 0.010 |
Why?
|
| Risk Factors | 1 | 2002 | 3876 | 0.010 |
Why?
|
| Adolescent | 1 | 2002 | 3539 | 0.010 |
Why?
|